{
    "clinical_study": {
        "@rank": "117695", 
        "acronym": "DIE-NIS", 
        "arm_group": {
            "arm_group_label": "Deep Infiltrating Endometriosis (DIE)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to describe changes in the intensity of specific endometriosis\n      symptoms from baseline pre-surgery to after surgery and subsequent continuous Diphereline\n      (Triptorelin Acetate) treatment for up to 24 weeks."
        }, 
        "brief_title": "A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Deep Infiltrating Endometriosis (DIE)", 
        "condition_browse": {
            "mesh_term": "Endometriosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients diagnosed with DIE and having received surgery treatment within one month\n             before inclusion\n\n          -  Premenopausal women aged >=18 years old.\n\n          -  Patient for whom the treating physician already made the decision to treat by\n             Diphereline.\n\n        Exclusion Criteria:\n\n          -  Pregnancy or lactation.\n\n          -  Patients currently on treatment or who have been on therapy with a GnRHa in the last\n             6 months.\n\n          -  Premenopausal women who may reach menopause within the 3 years post randomisation.\n\n          -  Hypersensitivity to Triptorelin or one of the excipients of Triptorelin 3.75mg"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Hospital patients who had been diagnosed with DIE, surgically treated and for whom\n        decision has been made to be treated with a GnRHa post-surgery."
            }
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01942369", 
            "org_study_id": "A-38-52014-210"
        }, 
        "intervention": {
            "arm_group_label": "Deep Infiltrating Endometriosis (DIE)", 
            "description": "Triptorelin Acetate is a Gonadotrophin Releasing Hormone agonist (GnRHa).\nTriptorelin acetate for injection 3.75mg administered as described in the patient information sheet approved in China: one intramuscular injection of the product repeated every 4 weeks.", 
            "intervention_name": "Triptorelin Acetate 3.75mg intramuscular injection", 
            "intervention_type": "Drug", 
            "other_name": "Diphereline 3.75mg intramuscular injection"
        }, 
        "intervention_browse": {
            "mesh_term": "Triptorelin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Endometriosis", 
        "lastchanged_date": "April 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hangzhou", 
                    "country": "China", 
                    "zip": "310006"
                }, 
                "name": "Women's Hospital, School of Medicine, Zhejiang University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multi-centre, Prospective, Non-interventional Study to Describe the Efficacy of a Continuous up to 24-week Treatment of Diphereline 3.75mg Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months.", 
        "overall_contact": {
            "email": "clinical.trials@ipsen.com", 
            "last_name": "Ipsen Recruitment Enquiries"
        }, 
        "overall_official": {
            "affiliation": "Ipsen", 
            "last_name": "Medical Director Uro-Oncology", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The specific endometriosis symptoms include pelvic pain, dysmenorrhoea, pain at time of ovulation, dyspareunia to be assessed with a 10-cm visual analogue scale (VAS).", 
            "measure": "Changes in the intensity of specific endometriosis symptoms from baseline pre-surgery", 
            "safety_issue": "No", 
            "time_frame": "Every 3 months in the first 12 months after surgery and every 6 months in the following 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01942369"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Recurrence rate of specific endometriosis symptoms in the group of patients with mild or null symptoms score following surgery and Diphereline treatment.", 
                "measure": "Recurrence rate of specific endometriosis symptoms", 
                "safety_issue": "No", 
                "time_frame": "At 12 months and 24 months"
            }, 
            {
                "measure": "Rate of pregnancy in subjects", 
                "safety_issue": "No", 
                "time_frame": "At 12 months and 24 months"
            }, 
            {
                "description": "Assessed using a visual analogue scale (VAS).", 
                "measure": "Abdominal pain-free interval", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months in the first 12 months after surgery and every 6 months in the following 12 months"
            }
        ], 
        "source": "Ipsen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ipsen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}